New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
16:07 EDTVRTXVertex submits sNDA to FDA for Kalydeco
Vertex Pharmaceuticals announced the submission of a supplemental New Drug Application, or sNDA, to the FDA for the approval of Kalydeco in people with cystic fibrosis, or CF, ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. In the United States, Kalydeco is currently approved for use in people with CF ages 6 and older who have one of the following nine mutations: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. CF is caused by a defective or missing CFTR protein that results from mutations in the CFTR gene. In the United States, approximately 300 people have the R117H mutation and are 18 years of age or older. R117H is the most common residual function mutation and also has a defect in the gating of the CFTR protein.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
09:06 EDTVRTXVertex names David Altshuler as Chief Scientific Officer
Subscribe for More Information
December 12, 2014
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use